PRESS RELEASES

First Feature Film NFT Drops from VUELE™ Grossing Nearly Six Figures In Four-Day Auction with Academy Award®-Winner Anthony Hopkins Thriller ZERO CONTACT

New Model Validates Hollywood’s Newest Revenue Stream via Blockchain Distribution BEVERLY HILLS, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — In a groundbreaking venture, global NFT distribution and viewing platform VUELE™ grossed nearly six figures bringing in 32.86267 ETH ($93,435) with the release of eleven total NFT drops of feature film thriller ZERO CONTACT starring Oscar-winning […]

PRESS RELEASES

B2B Lead Generation Company bant.io Now Accepts Cryptocurrency to Serve a Vibrant Startup Economy

bant.io has become the first B2B lead generation organization to deal in cryptocurrency. bant.io dashboard LONDON, Sept. 29, 2021 (GLOBE NEWSWIRE) — bant.io, the all-in-one B2B lead generation and sales acceleration service, is pushing at the boundaries of conventional business practice. The B2B lead generation agency will now accept cryptocurrency as payment for its services […]

PRESS RELEASES

Delphix Data Control Tower Achieves SOC 2 Type 1 Compliance

Report Validates Security Protocols of Delphix’s Masking, Compliance, and SaaS Capabilities REDWOOD CITY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — Delphix, the industry leading data company for DevOps, today announced that it has successfully completed a Type 1 System and Organization Controls (SOC) 2 examination for the Delphix Data Control Tower (DCT). The examination, conducted […]

PRESS RELEASES

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma – Health Canada Issues Conditional Approval of TRUSELTIQ under Project Orbis (September 27th, 2021) LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 – Helsinn Group and BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate […]